ArticleJournal of cellular and molecular medicine2026
Serum Leptin Exacerbates Osteoarthritis by Promoting Subchondral Bone H-Type Vessel Angiogenesis via Activation of the PI3K/AKT Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correction to 'Serum Leptin Exacerbates Osteoarthritis by Promoting Subchondral Bone H-Type Vessel Angiogenesis via Activation of the PI3K/AKT Pathway'.Journal of cellular and molecular medicine · 2026Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA) is a common degenerative joint disease closely associated with obesity. Adipokines secreted by adipose tissue play critical roles in disease progression. This study focuses on the adipokine leptin and investigates its relationship with knee osteoarthritis. Analysis of subchondral bone tissue from OA patients revealed decreased leptin receptor expression, enhanced osteogenic activity, and a significant increase in H-type vessel number. Concurrently, serum leptin levels were markedly elevated in OA patients. Animal experiments further demonstrated that leptin-knockout obese mice exhibited significantly milder OA, reduced H-type vessel formation, and decreased osteogenic activity. In contrast, mice with high serum leptin levels showed more severe joint destruction and vascular hyperplasia. In vitro cell experiments indicated that leptin activates the PI3K/AKT signalling pathway in bone marrow mesenchymal stem cells (BMSCs), increasing the secretion of angiogenic factors such as VEGF and HIF-1α. Conditioned medium from leptin-treated BMSCs promoted tube formation and expression of H-type vessel markers (EMCN/CD31) in mouse umbilical vein endothelial cells. Inhibition of the PI3K pathway using Ly294002 in BMSCs or ZSTK474 in mice abolished leptin's effects. These results suggest that obesity-induced hyperleptinemia drives aberrant H-type vessel angiogenesis and active bone remodelling in subchondral bone via the PI3K/AKT pathway, thereby accelerating OA progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.